Case report

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series

Lawrence Kasherman a,1, Swati Garg a,1, Nairi Tchrakian b, Blaise Clarke b, Katherine Karakasis a, Raymond H. Kim b,c, Tracy L. Stockley b,d,e, Neesha Dhani a, Amit M. Oza a, Stephanie Lheureux a,*

a Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada
b Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
c Familial Cancer Clinic, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada
d Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
e Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON

ARTICLE INFO

Keywords:
High grade serous ovarian cancer
TP53 variant negative
P53 immunohistochemistry
Diagnosis
Next generation sequencing

1. Introduction

Ovarian cancer (OC) accounts for the second leading cause of gynecologic malignancies worldwide with high-grade serous ovarian carcinoma (HGSOC) being the most common subtype (Torre et al., 2018). Tumor TP53 variants are an important hallmark of HGSOC with nearly all being TP53 variant positive (Network CGAR, 2011), and can potentially guide disease monitoring and treatment response on circulating tumor DNA (ctDNA) (Parkinson et al., 2016). However, careful review of integrated genomic data from The Cancer Genome Atlas (TCGA) study reveals that ~4% of HGSOC are TP53 variant negative (Network CGAR, 2011). Historically, immunohistochemistry (IHC) has been used for the detection of p53 abnormalities in OC and is nearly 100% predictive of tumor TP53 mutational status, leading to routine use in diagnosis (Köbel et al., 2016). p53 IHC expression falls under the following categories: overexpression, complete absence, cytoplasmic or wild type (Köbel et al., 2016). However, IHC cannot identify specific TP53 mutations and thus cannot be used for monitoring. It is important to understand alternative approaches considered in the absence of TP53 variants in HGSOC.

At our Centre, we initiated the Biomarker Discovery Project in High Grade Serous Ovarian Cancer (BioDIVA, NCT03419689), through which genomic profiling data is collected for each subject with a histologically confirmed HGSOC diagnosis. Tumor profiling for enrolled subjects was completed in a College of American Pathologists/Clinical Laboratory Improvement Amendment (CAP/CLIA)-accredited laboratory using a multigene targeted panel spanning exonic regions of 555 cancer-related genes (UHN Hi5 Panel) (Lheureux et al., 2018). Germline testing using 23-gene panel comprised of genes related to high-risk breast and/or ovarian cancers was also performed routinely through the Familial Cancer Clinic.

In this case series, we describe the histopathological, immunohistochemical and genetic attributes of three TP53 variant negative cases identified in BioDIVA, which raise questions regarding diagnostic and therapeutic considerations in this subset of HGSOC.
2. Case presentation 1

A 52-year-old was diagnosed incidentally from unilateral salpingo-oophorectomy, and underwent upfront debulking surgery confirming Stage IIIB HGSOC after central gynecology pathology review (Fig. 1A). p53 immunostains showed diffuse overexpression in the tumor (Fig. 2A-B), and positive PAX8 and WT-1. Pathogenic germline BRCA1 variant (c.3342delA; p.Glu1115Lysfs*2) was detected and strong familial cancer history was noted. Tumor profiling from surgical specimen did not reveal TP53 variant, but confirmed the presence of BRCA1 variant, and rare PARP1 variant (c.2905G > A; p.Val969Ile) of uncertain significance. The patient exhibited a serous tubal intraepithelial carcinoma (STIC) lesion (Fig. 2C), which also demonstrated diffuse p53 IHC overexpression (Fig. 2D) and moderately increased Ki67 proliferative index (Fig. 2E). She received adjuvant cisplatin and paclitaxel then maintenance olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, continuing beyond one year (Fig. 1A).

Fig. 1. Timeline describing oncological history of individual patient following initial diagnosis and throughout the course of treatment until current for A) Patient 1, B) Patient 2, and C) Patient 3.
3. Case presentation 2

A 48-year-old was diagnosed with stage IIIA HGSOC on omental biopsy, arising from the right fallopian tube associated with STIC lesion (Fig. 2F). p53 immunostaining on central gynecological pathology review showed null-type staining in both invasive tumor and STIC (Fig. 2G-H), and expression of PAX8 and WT-1. She received neo-adjuvant carboplatin and paclitaxel, underwent interval debulking to no residual disease, and completed adjuvant chemotherapy. Subsequently, she developed recurrent disease and was treated with multiple lines of chemotherapy and olaparib, and passed away nearly three years from date of diagnosis (Fig. 1B). Tumor profiling indicated absence of TP53 variant, and presence of a rare PARP1 variant (c.172 T > C, p. Trp58Arg) of uncertain significance. Germline panel testing results were negative, and family history was notable for lung cancer in her father and aunt.

4. Case presentation 3

A 51-year-old was diagnosed with stage IIIC high-grade serous peritoneal carcinoma on omental biopsy (Fig. 2I). IHC on both specimens was confirmatory of serous Müllerian tumor (PAX8 and WT-1 expression), and p53 staining was null-type (Fig. 2J). She received neo-adjuvant carboplatin and paclitaxel, interval debulking to no residual disease then further chemotherapy followed by maintenance olaparib, which continues beyond one year. She harbors pathogenic germline BRCA1 variant (c.1480C > T, p.Gln494*). Tumor profiling from surgical specimen identified the germline BRCA1 variant and did not detect TP53 variants (Supplementary Table 1). She has no familial cancer history.

5. Discussion

A wide variety of clinical, imaging and laboratory parameters inform
the diagnosis of HGSOC (Fig. 3). TP53 variants are the most frequent genomic alterations in human cancers leading to loss-of-function, dominant-negative or gain-of-function phenotypes, and thus lead to carcinogenesis, metastasis and development of chemo-resistance (Zhang et al., 2016). True TP53 variant negative HGSOC is a rare phenomenon, and absence of TP53 variants through NGS poses a diagnostic dilemma which should lead to critical re-evaluation of all considerations for a conclusive diagnosis. In this case series, we shed light on the significance of each of these factors in aiding with confirmation of final pathological diagnosis of this rare subset of HGSOC.

5.1. p53 by immunohistochemistry or NGS

Abnormal p53 IHC expression is a robust surrogate marker for TP53 mutations (Köbel et al., 2016) and is routinely used in diagnosing HGSOC as recommended by the World Health Organization (Köbel et al., 2016; Carcangiu et al., 2014). However, in each of the cases detailed above, abnormal p53 IHC was observed despite the lack of TP53 mutation identified by tumor profiling, and outcomes of this particular subgroup have not been explored previously. One crucial limitation of tumor specimens is that they only allow pathological and genomic assessment at a single time point, which is affected by quality of samples assessed and tumor heterogeneity. In our case series, tissue biopsies sequenced from two of the three cases reported here met optimal tumor cellularity requirements (>20% tumor cellularity, to detect mutations to 3–5% variant allele frequency) for NGS assays, whereas one was below the standard cellularity accepted (5–10%)(Supplementary Table 1).

Unfortunately, in all three cases presented, tissue sampling was not adequate to perform repeated sequencing, which would have been especially useful in the case where cellularity was below standard. NGS assays only detect TP53 mutations in regions covered by the assay (in this case, exonic regions and 5–10 bp of flanking intronic regions), and use of short-read NGS methods may not detect rare TP53 variants, such as large insertions or deletions. Conversely, although IHC correlates well with NGS (Köbel et al., 2016), the tests differ in their sensitivities and specificities, and occasionally lead to false positives. In some tumors aberrant p53 expression may also be linked to alterations in p53 regulators such as MDM2, p14-ARF and other molecular chaperones that control stabilization (Xue et al., 2019; Wang et al., 2005). Using a combination of both assays is suggested for the most accurate classification; however, the dilemma remains as to which results are prioritized when discrepancies are present. (Köbel et al., 2016). Further investigation could be pursued through whole exome or genome sequencing. Although IHC may be more relevant for diagnostic characterization of HGSOC, knowledge of TP53 mutation status is required for disease monitoring purposes using ctDNA. Even though the clinical implications of knowing the exact TP53 variant status is limited currently, in a recent report by Oza et al., differential clinical benefit by Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin combination in women with HGSOC was observed with different TP53 mutation subtypes (Oza et al., 2020).

5.2. STIC lesions

The presence of STIC lesions, optimally diagnosed through sampling via the SEE-FIM (Sectioning and Examining Extensively the FIMbriated end) protocol may be indicative of HGSOC diagnosis (Medeiros et al., 2006), as several studies have indicated they are precursory and arise from tubal epithelium years prior to malignant transformation (Zhang et al., 2019). Genomic assessments of STIC lesions consistently demonstrate that TP53 variants are early driving events for HGSOC, although some differences in TP53 status between precursor and carcinoma lesions may exist due to evolutionary changes and clonal diversity (Zhang et al., 2019). In our study, two cases demonstrated STIC lesions in histopathological specimens (Fig. 2), which showed identical mutant staining patterns on IHC compared with the accompanying invasive tumors.

5.3. BRCA mutations

The presence of BRCA1/2 variants, together with loss-of-heterozygosity of the wild-type BRCA1/2 allele, work synergistically with dysfunctional p53 pathways causing carcinogenesis (Sower and Ashworth, 2005). Although the presence of a TP53 variant is ubiquitous in BRCA-mutated HGSOC, careful review of large genomic datasets from AACR-GENIE, TCGA and other studies (Boyarshikh et al., 2020) showed a small subset of patients without TP53 variants but BRCA1/2 variant positive (Supplementary Figs. 1 and 2). Additionally, one report of 25 TP53 variant-negative HGSOC cases highlighted nine cases with homologous recombination repair pathway abnormalities (Chui et al., 2020). In our series, two patients were TP53 variant negative with pathogenic germline BRCA1 variants. This observation is similar to recent reports (Boyarshikh et al., 2020) in BRCA1/2 mutant HGSOC, however no CDKN2A variants were seen.

Amongst other mutational events, it is interesting to note that two patients exhibited presence of rare PARP1 variants, classified as variants of uncertain significance. PARP1 proteins are involved in processes such as DNA repair, replication, transcription and chromatin remodeling (Jiang et al., 2015), and mutations have been linked to altered sensitivity towards PARP inhibitors (Petitti et al., 2018). In the patients described, the presence of PARP1 variants did not appear to affect response to PARP inhibition. The predictive role of PARP1 variants in the context of TP53 variant negative HGSOC is yet to be established.

In conclusion, this report summarizes three cases of HGSOC with abnormal p53 IHC, without TP53 variants on tumor molecular profiling, examining exonic regions. Our findings support that contrary to TP53 mutational status, p53 immunostaining patterns along with morphological parameters are more robust in distinguishing serous carcinomas as low-grade versus high-grade. This study highlights the importance of using a combination of NGS and non-NGS assays in assessing the p53 functional status for clinical trial inclusion, as well reviewing other evaluators in order to overcome the possibility of misdiagnosis. This may include: 1) re-evaluation of clinico-pathological features; 2) genetic re-assessment through more comprehensive assays, such as whole genome and ctDNA analysis (Patch et al., 2015; Imperial et al., 2019) to ensure no missed rare or complex genomic variants, preferably on different tissue samples; and 3) ensuring optimal quality and quantity of tumor sample is used. This study also emphasizes the difficulty in relying on p53 abnormality as the sole diagnostic marker in HGSOC, since some tumors which are morphologically HGSOC (approximately 4%) may have wild-type p53 staining pattern (Köbel et al., 2016). Most interestingly, this study highlights the importance of identification of additional genomic variants in HGSOC patients where TP53 variants are not detected by NGS. The information on BRCA1 and/or PARP variants if available upfront at the onset of treatment, could influence the treatment plan. Two of the three patients in our study carried PARP variants, and therefore, might not have been treated with PARP inhibitors. These findings are important as that may lead to the development of a customized panel that will define an increasingly refined approach to determining unique molecular signatures for HGSOC. Lastly, this study emphasizes reconsidering diagnosis of HGSOC when tumors are TP53 variant negative by NGS and/or p53 IHC wild type.

6. Author contributions**a

Study conception and design was performed by LK, SG and SL; Study supervision by SL, ND and AMO; funding acquisition performed by SL, AMO and KK; Data curation, analysis and manuscript writing by LK and SG; pathology review was performed by BC and NT; genomic testing was done under the supervision of TLS; germline review was performed by BK. Final review was done by all authors.
7. Consent**a

Written informed consent was obtained from the patients as part of the BioDIVA study (NCT03419689), which was approved by the University Health Network Research Ethics Board, for collection of tumor tissue and blood for genomic profiling as well as publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

8. Funding**a

This study was conducted through BioDIVA (NCT03419689), which was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gore.2021.100729.

References

Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., 2018. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68, 284–296.

Network CGAR, 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609.

Parkinson, C.A., Gale, D., Piskorz, A.M., Biggs, H., Hodgkin, C., Addley, H., et al., 2016. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 13, e1002198.

Köbel, M., Piskorz, A.M., Lee, S., Lui, S., LePage, C., Marass, F., et al., 2016. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J. Pathol.: Clin. Res. 2, 247–258.

Lheureux, S., Tinker, A., Clarke, B., Ghatage, P., Welch, S., Weberpals, J.L., et al., 2018. A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium. Clin. Cancer Res. 24, 6168–6174.

Zhang, Y., Cao, L., Nguyen, D., Hu, H., 2016. TP53 mutations in epithelial ovarian cancer. Translational cancer research. 5, 650.

Carcangiu, M., Kirman, R.J., Carcangiu, M.L., Herrington, C.S., 2014. WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer.

Xue, Y., San Luis, B., Lane, D.P., 2019. Intratumour heterogeneity of p53 expression; causes and consequences. J. Pathol. 249, 274–285.

Wang, Y.-C., Lin, R.-K., Tan, Y.-H., Chen, J.-T., Chen, C.-Y., Wang, Y.-C., 2005. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J. Clin. Oncol. 23, 154–164.

Oza, A.M., Estève-Díaz, M., Grischke, E.-M., Hall, M., Marmè, F., Provencher, D., et al., 2020. A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin. Cancer Res. 26, 4767–4776.

Medeiros, F., Muto, M.G., Lee, Y., Elvin, J.A., Callahan, M.J., Feltmate, C., et al., 2006. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30, 230–236.

Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D.A., Neel, B.G., 2019. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat. Commun. 10, 1–16.

Sower, H.M., Ashworth, A., 2005. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 26, 1651–1656.

Boyarskikh, U.A., Gulyaeva, L., Avdalyan, A., Kechin, A., Khrapov, E., Lazareva, D., et al., 2020. Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer. Front. Oncol. 10, 1103.

Chui, M.H., Borojeni, A.M., Mandelker, D., Ladanyi, M., Soslow, R.A., 2020. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Mod. Pathol. 1–12.

Jiang, B.-H., Tseng, W.-L., Li, H.-Y., Wang, M.-L., Chang, Y.-L., Sung, Y.-J., et al., 2015. Poly (ADP-ribose) polymerase 1: cellular pluripotency, reprogramming, and tumorigenesis. Int. J. Mol. Sci. 16, 15531–15545.

Pettitt, S.J., Krastev, D.B., Brandshina, I., Dzian, A., Song, F., Aleksandrov, R., et al., 2018. Genome-wide and high density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9, 1–14.

Patch, A.-M., Christie, E.L., Etemadmoghadam, D., Garsed, D.W., George, J., Fereday, S., et al., 2015. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494.

Imperial, R., Nazer, M., Ahmed, Z., Kam, A.E., Phurd, T.J., Bahaj, W., et al., 2019. Matched whole-genome sequencing (WGS) and whole-exome sequencing (WES) of tumor tissue with circulating tumor DNA (ctDNA) analysis: Complementary modalities in clinical practice. Cancers. 11, 1399.